|
|
|
| QT interval monitoring and clinical risk assessment in patients with cancer therapy |
| CHENG Siyao1, GENG Xuhong1, PAN Shuo1, WANG Li1, WANG Yan1, CAO Youyu2, LIU Tong3 |
|
|
|
Abstract Besides conventional chemotherapy, cancer therapy also includes biotargeted therapy, endocrine therapy and immune checkpoint inhibitor therapy and so on at present. Cardiovascular adverse events associated with cancer therapy arouse much attention, among which QT interval prolongation as an abnormal ventricular repolarization phenomenon related to many cancer therapeutic drugs may induce torsades de pointes. Currently known factors that affect QT interval include medications, heart rate, electrolyte disturbances, etc. Based on the latest research progress at home and abroad, this paper reviews the measurement and influencing factors of QT interval, grading of QTc related adverse events, antitumor drugs leading to QT interval prolongation and adjuvant medications, and monitoring and management strategies of QT interval in patients with cancer therapy.
|
|
|
|
|
|
| [1] |
. [J]. JOURNAL OF PRACTICAL ELECTROCARDIOLOGY, 2024, 33(1): 78-81. |
|
|
|
|
